BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trachalaki A, Irfan M, Wells AU. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert Opin Pharmacother 2021;22:191-204. [PMID: 32993388 DOI: 10.1080/14656566.2020.1822326] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Lian N, Jin H, Zhu W, Zhang C, Qi Y, Jiang M, Mao J, Lu X, Zhao F, Xi B, Qi X, Li Y. Inhibition of glutamine transporter ASCT2 mitigates bleomycin-induced pulmonary fibrosis in mice. Acta Histochemica 2022;124:151961. [DOI: 10.1016/j.acthis.2022.151961] [Reference Citation Analysis]
2 Khalajzeyqami Z, Grandi A, Ferrini E, Ravanetti F, Leo L, Mambrini M, Giardino L, Villetti G, Stellari FF. Pivotal role of micro-CT technology in setting up an optimized lung fibrosis mouse model for drug screening. PLoS ONE 2022;17:e0270005. [DOI: 10.1371/journal.pone.0270005] [Reference Citation Analysis]
3 Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205:e18-47. [PMID: 35486072 DOI: 10.1164/rccm.202202-0399ST] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 77.0] [Reference Citation Analysis]
4 Lei S, Li X, Xie Y, Li J. Clinical evidence for improving exercise tolerance and quality of life with pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Clin Rehabil 2022;:2692155221095481. [PMID: 35481421 DOI: 10.1177/02692155221095481] [Reference Citation Analysis]
5 Chen D, Tang H, Jiang H, Sun L, Zhao W, Qian F. ACPA Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-β-Smad2/3 Signaling-Mediated Lung Fibroblast Activation. Front Pharmacol 2022;13:835979. [PMID: 35355726 DOI: 10.3389/fphar.2022.835979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shen H, Zhang N, Liu Y, Yang X, He Y, Li Q, Shen X, Zhu Y, Yang Y. The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Front Pharmacol 2021;12:805535. [PMID: 35069217 DOI: 10.3389/fphar.2021.805535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Zang C, Zheng Y, Wang Y, Li L. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. Eur J Med Res 2021;26:129. [PMID: 34717762 DOI: 10.1186/s40001-021-00601-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sivakumar P, Ammar R, Thompson JR, Luo Y, Streltsov D, Porteous M, McCoubrey C, Cantu E 3rd, Beers MF, Jarai G, Christie JD. Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis. Respir Res 2021;22:273. [PMID: 34689792 DOI: 10.1186/s12931-021-01860-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
9 Trachalaki A, Tsitoura E, Mastrodimou S, Invernizzi R, Vasarmidi E, Bibaki E, Tzanakis N, Molyneaux PL, Maher TM, Antoniou K. Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. Front Immunol 2021;12:661811. [PMID: 34220810 DOI: 10.3389/fimmu.2021.661811] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
10 Elowsson Rendin L, Löfdahl A, Kadefors M, Söderlund Z, Tykesson E, Rolandsson Enes S, Wigén J, Westergren-Thorsson G. Harnessing the ECM Microenvironment to Ameliorate Mesenchymal Stromal Cell-Based Therapy in Chronic Lung Diseases. Front Pharmacol 2021;12:645558. [PMID: 34040521 DOI: 10.3389/fphar.2021.645558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]